DryNeb™ Dry Powder Nebulizer is initially being targeted at LRI therapies for which there is a large unmet need: viral infections, fungal infections, bacterial infections of lung.
The Platform technology is also be able to deliver drugs that treat lung cancer and other deadly lung diseases. The targeted delivery will minimize drug side effects/toxicities and provide high concentrations of drug to the site of disease/infection.
The company has recently successfully achieved several key milestones as part of an early assessment of an inhaled anti-fungal agent through an NIH SBIR Phase I award and is now seeking funding to commence the clinical development program of this important therapeutic. In addition, in-vitro evaluations are being conducted to establish other potential clinical applications of the DryNeb™